Vigeo Therapeutics Inc, based in Cambridge, MA, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for various types of cancer to enhance patient outcomes. Their focus lies in reprogramming the tumor immune microenvironment (TIME) through the activation of thrombospondin-1 (Tsp-1), a natural anti-tumorigenic protein that combats cancer cells and inhibits metastasis.
Currently, Vigeo is conducting clinical trials for VT1021, a peptide therapeutic agent, in patients with pancreatic, ovarian, triple negative breast cancers, glioblastoma, and tumors with elevated levels of CD36. Their mission is to revolutionize cancer treatment by harnessing the body's own defenses against cancer and improving the lives of those affected by the disease.
Generated from the website
